•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Looking At Avadel Pharmaceuticals's Recent Unusual Options Activity
Harrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?
Oppenheimer Reaffirms Their Buy Rating on Avadel Pharmaceuticals (AVDL)
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024
Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024
Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
Avadel gains for a second day as analysts see it prevailing in case vs Jazz/FDA
Avadel Pharma gains during hearing over dispute on FDA approval of a sleep disorder drug
Buy Rating Affirmed for Avadel Pharmaceuticals Amidst Strong Growth Potential and Market Expansion
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q1 2024 Earnings Call Transcript
Q1 2024 Avadel Pharmaceuticals PLC Earnings Call Transcript
Analysts Offer Insights on Healthcare Companies: Definitive Healthcare Corp (DH) and Avadel Pharmaceuticals (AVDL)
Avadel Pharmaceuticals Reports First Quarter 2024 Earnings: Revenue Surpasses Estimates but Net ...
Avadel Pharmaceuticals GAAP EPS of -$0.30 misses by $0.29, revenue of $27.18M beats by $1.28M
Avadel Pharmaceuticals Reports First Quarter 2024 Earnings: Revenue Surpasses Estimates but Net Loss Widens
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.